NICOX SA (COX.PA) Stock Price, Forecast & Analysis

EPA:COX • FR0013018124

0.579 EUR
0 (-0.52%)
Last: Apr 27, 2023, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership

COX.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap28.92M
Revenue(TTM)3.27M
Net Income(TTM)-27.76M
Shares49.94M
Float46.22M
52 Week High2.09
52 Week Low0.55
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.61
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO1999-11-02
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
COX.PA short term performance overview.The bars show the price performance of COX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

COX.PA long term performance overview.The bars show the price performance of COX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of COX.PA is 0.579 EUR. In the past month the price decreased by -8.1%. In the past year, price decreased by -66.14%.

NICOX SA / COX Daily stock chart

COX.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
COX.PA Full Technical Analysis Report

COX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to COX.PA. COX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
COX.PA Full Fundamental Analysis Report

COX.PA Financial Highlights

Over the last trailing twelve months COX.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 47.58% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.47
Chartmill High Growth Momentum
EPS Q2Q%74.55%
Sales Q2Q%-68.85%
EPS 1Y (TTM)47.58%
Revenue 1Y (TTM)-54.78%
COX.PA financials

COX.PA Forecast & Estimates

8 analysts have analysed COX.PA and the average price target is 2.91 EUR. This implies a price increase of 402.07% is expected in the next year compared to the current price of 0.579.

For the next year, analysts expect an EPS growth of 35.92% and a revenue growth 16.23% for COX.PA


Analysts
Analysts85
Price Target2.91 (402.59%)
EPS Next Y35.92%
Revenue Next Year16.23%
COX.PA Analyst EstimatesCOX.PA Analyst Ratings

COX.PA Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
COX.PA Ownership

COX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
1AE ARGENX SE28.0343.974B
ARGX ARGENX SE27.8843.95B
22UA BIONTECH SE-ADR N/A21.593B
ABVX ABIVAX SA N/A8.54B
2X1 ABIVAX SA N/A8.445B
GLPG GALAPAGOS NV N/A1.875B
GXE GALAPAGOS NV N/A1.874B
IVA INVENTIVA SA N/A1.081B
NANO NANOBIOTIX N/A1.079B
6IV INVENTIVA SA N/A1.075B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About COX.PA

Company Profile

COX logo image Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Company Info

NICOX SA

Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis

Valbonne PACA FR

Employees: 32

COX Company Website

Phone: 33497245300.0

NICOX SA / COX.PA FAQ

What does NICOX SA do?

Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.


What is the stock price of NICOX SA today?

The current stock price of COX.PA is 0.579 EUR. The price decreased by -0.52% in the last trading session.


Does NICOX SA pay dividends?

COX.PA does not pay a dividend.


How is the ChartMill rating for NICOX SA?

COX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for NICOX SA?

NICOX SA (COX.PA) operates in the Health Care sector and the Biotechnology industry.


Would investing in NICOX SA be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on COX.PA.


Can you provide the market cap for NICOX SA?

NICOX SA (COX.PA) has a market capitalization of 28.92M EUR. This makes COX.PA a Nano Cap stock.